RT Journal Article
SR Electronic
T1 Common genetic variants identify therapeutic targets for COVID-19 and individuals at high risk of severe disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.14.20248176
DO 10.1101/2020.12.14.20248176
A1 J. E. Horowitz
A1 J. A. Kosmicki
A1 A. Damask
A1 D. Sharma
A1 G. H. L. Roberts
A1 A. E. Justice
A1 N. Banerjee
A1 M. V. Coignet
A1 A. Yadav
A1 J. B. Leader
A1 A. Marcketta
A1 D. S. Park
A1 R. Lanche
A1 E. Maxwell
A1 S. C. Knight
A1 X. Bai
A1 H. Guturu
A1 D. Sun
A1 A. Baltzell
A1 F. S. P. Kury
A1 J. D. Backman
A1 A. R. Girshick
A1 C. O’Dushlaine
A1 S. R. McCurdy
A1 R. Partha
A1 A. J. Mansfield
A1 D. A. Turissini
A1 A. H. Li
A1 M. Zhang
A1 J. Mbatchou
A1 K. Watanabe
A1 L. Gurski
A1 S. E. McCarthy
A1 A. Verma
A1 G. Sirugo
A1 Regeneron Genetics Center
A1 M. D. Ritchie
A1 M. Jones
A1 S. Balasubramanian
A1 W. J. Salerno
A1 A. R. Shuldiner
A1 D. J. Rader
A1 T. Mirshahi
A1 A. E. Locke
A1 J. Marchini
A1 J. D. Overton
A1 D. J. Carey
A1 L. Habegger
A1 M. N. Cantor
A1 K. A. Rand
A1 E. L. Hong
A1 J. G. Reid
A1 C. A. Ball
A1 A. Baras
A1 G. R. Abecasis
A1 M. A. Ferreira
YR 2020
UL http://medrxiv.org/content/early/2020/12/16/2020.12.14.20248176.abstract
AB The need to identify and effectively treat COVID-19 cases at highest risk for severe disease is critical. We identified seven common genetic variants (three novel) that modulate COVID-19 susceptibility and severity, implicating IFNAR2, CCHCR1, TCF19, SLC6A20 and the hyaluronan pathway as potential therapeutic targets. A high genetic burden was strongly associated with increased risk of hospitalization and severe disease among COVID-19 cases, especially among individuals with few known risk factors.Competing Interest StatementJ.E.H., J.A.K., A.D., D.S., N.B, A.Y., A.M., R.L., E.M., X.B., H.G., D.S., F.S.P.K., J.D.B., C.O., A.J.M., D.A.T., A.H.L., J.M., K.W., L.G., S.E.M, M.J., S.B., W.J.S., A.R.S., A.E.L., J.M., J.O., L.H., M.N.C., J.G.R., A.B., G.R.A., and M.A.F. are current employees and/or stockholders of Regeneron Genetics Center or Regeneron Pharmaceuticals. G.H.L.R., M.V.C., D.S.P., S.C.K. A.Bal., A.R.G., S.R.M., R.P., M.Z., K.A.R., E.L.H., C.A.B. are current employees at AncestryDNA and may hold equity in AncestryDNA. The other authors declare no competing interests.Funding StatementThe Penn Medicine BioBank is funded by a gift from the Smilow family, the National Center for Advancing Translational Sciences of the National Institutes of Health under CTSA Award Number UL1TR001878, and the Perelman School of Medicine at the University of Pennsylvania. All other authors have no sources of funding to acknowledge.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UK Biobank obtained ethical approval for this study by the North West Multicenter Research Ethics Committee and all participants gave written informed consent to participate and be followed up. All additional participants from the Geisinger Health System MyCode Community Health Initiative, University of Pennsylvania Penn Medicine BioBank, and AncestryDNA customers provided informed consent to participate in research under IRB-approved protocols at each institution. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll genotype-phenotype association results reported in this study are available for browsing using the RGC’s COVID-19 Results Browser (https://rgc-covid19.regeneron.com). Data access and use is limited to research purposes in accordance with the Terms of Use (https://rgc-covid19.regeneron.com/terms-of-use).